BioWorld looks at translational medicine, including: Mechanisms of retinopathy come into focus; New partner in crime for AHR; Multiple sclerosis’ early days; MMA induces EMT; CAR T cells for inhibition; Islet organoids can evade immune attack, Cross-reactive immunity helps antitumor response; How antidepressants inhibit fibrosis; Just add fever.
Keeping you up to date on recent developments in diagnostics, including: Antigen test detects spike proteins of SARS-CoV-2; Blood volume assessment study to use Daxor device; Gaining insights into loss of function.
Stimulator of interferon genes (STING) is a protein that senses DNA in the cytosol, where it comes from either an infectious invader or a damaged nucleus and sets off an immune response that ultimately results in the activation of T cells. STING agonists are among the strategies that have been tested in hopes they would increase the response rate to checkpoint blockade. Now, back-to-back papers in the Aug. 21, 2020, issue of Science have detailed the preclinical development of orally available STING agonists.
Keeping you up to date on recent developments in oncology, including: New and less expensive approach to digital PCR may improve cancer detection; Stromal cell subtypes identified in TNBC; Microbiome metabolites as immunotherapy adjuvants; Pandemic significantly impeded breast cancer follow-up.
Keeping you up to date on recent developments in neurology, including: Combining genetic information with EMRs to pinpoint childhood epilepsies; AI-enhanced precision medicine identifies novel autism subtype; From variants to treatments in neurology.
Triggering receptor expressed on myeloid cells 2 (TREM2) was first discovered because variants affect the risk of developing late-onset Alzheimer’s disease (AD).
Keeping you up to date on recent developments in diagnostics, including: GEP tests poor predictors of melanoma recurrence; A nonfasting blood test for diabetes; Starving out Chlamydia.
Keeping you up to date on recent developments in oncology, including: Novel nanoparticle releases therapy via DNA sequence trigger; In AML, collapse prevents relapse; The next great nano-thing: nanopaper.
Investigators have developed a new approach to classifying neurodegenerative disorders that used the overall patterns of protein aggregation, rather than specific proteins, to define six clusters of patients that crossed traditional diagnostic categories.
Investigators at Weill Cornell Medical College have demonstrated that mitochondrial DNA drives the abscopal antitumor response to radiation, which can be boosted by autophagy inhibition.
